1. Home
  2. ROMA vs GANX Comparison

ROMA vs GANX Comparison

Compare ROMA & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Roma Green Finance Limited

ROMA

Roma Green Finance Limited

HOLD

Current Price

$5.40

Market Cap

134.6M

Sector

Finance

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$2.43

Market Cap

112.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ROMA
GANX
Founded
2018
2017
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.6M
112.7M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
ROMA
GANX
Price
$5.40
$2.43
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.00
AVG Volume (30 Days)
496.9K
640.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
47.95
EPS
N/A
N/A
Revenue
N/A
$55,180.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.72
$1.41
52 Week High
$8.88
$4.34

Technical Indicators

Market Signals
Indicator
ROMA
GANX
Relative Strength Index (RSI) 77.84 49.87
Support Level $2.05 $1.60
Resistance Level $8.88 $2.93
Average True Range (ATR) 0.86 0.27
MACD 0.36 0.01
Stochastic Oscillator 53.75 36.41

Price Performance

Historical Comparison
ROMA
GANX

About ROMA Roma Green Finance Limited

Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: